Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Auspex Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Teva Pharmaceuticals, Inc. - ASPX

TEVA

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Auspex Pharmaceuticals, Inc.

NEW YORK, April 3, 2015 /PRNewswire/ -- Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Auspex Pharmaceuticals Inc. ("Auspex" or the "Company") (NasdaqGM: ASPX) for potential breaches of fiduciary duties in connection with the sale of the Company to Teva Pharmaceutical Industries Ltd. ("Teva") (NYSE: TEVA) for approximately $3.5 billion.  The Company's stockholders will receive $101 in cash for each share of Auspex common stock they own.

Faruqi & Faruqi, LLP.

Click here for more information: www.faruqilaw.com/ASPX. There is no cost or obligation to you.

The investigation focuses on whether Auspex' Board of Directors breached their fiduciary duties to the Company's stockholders by failing to conduct a fair sales process and whether and by how much this proposed transaction undervalues the Company to the detriment of Auspex' shareholders.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation.  The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation.  The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

If you own common stock in Auspex and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/ASPX or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330. 

Contact:
Faruqi & Faruqi, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Juan E. Monteverde, Esq.
jmonteverde@faruqilaw.com
Toll Free: (877) 247-4292
Phone:   (212) 983-9330

Attorney Advertising. (C) 2015 Faruqi & Faruqi, LLP.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.

Logo - http://photos.prnewswire.com/prnh/20120119/MM38856LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-faruqi--faruqi-llp-announces-the-investigation-of-auspex-pharmaceuticals-inc-over-the-proposed-sale-of-the-company-to-teva-pharmaceuticals-inc---aspx-300060973.html

SOURCE Faruqi & Faruqi, LLP



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today